We are live on
!
Find out more
Marshall Wace Portfolio holdings
AUM
$100B
1-Year Est. Return
35.1%
This Fund
S&P 500
This Quarter
Est. Return
+10%
1 Year Est. Return
+35.1%
3 Year Est. Return
+111.04%
5 Year Est. Return
+146.93%
10 Year Est. Return
+631.22%
AUM
$44.5B
AUM Growth
-$1.18B
(-2.6%)
Cap. Flow
-$4.15B
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
9.83%
Holding
3,927
New
652
Increased
690
Reduced
847
Closed
1,056
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Biogen
BIIB
|
+$309M |
| 2 |
ExxonMobil
XOM
|
+$302M |
| 3 |
Amazon
AMZN
|
+$291M |
| 4 |
Citigroup
C
|
+$253M |
| 5 |
Shopify
SHOP
|
+$238M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Humana
HUM
|
+$383M |
| 2 |
Johnson & Johnson
JNJ
|
+$312M |
| 3 |
JPMorgan Chase
JPM
|
+$285M |
| 4 |
AT&T
T
|
+$191M |
| 5 |
Dollar General
DG
|
+$187M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 15.63% |
| 2 | Financials | 15.61% |
| 3 | Technology | 14.28% |
| 4 | Consumer Discretionary | 13.21% |
| 5 | Industrials | 5.22% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
2526
Olema Pharmaceuticals
OLMA
$977M
| $310K | ﹤0.01% |
126,649
-20,185
| -14% | -$58.9K |
|
2527
Sterling Infrastructure
STRL
$15.2B
| $310K | ﹤0.01% |
+9,449
| New | +$278K |
|
|
AZRE
2528
DELISTED
Azure Power Global Limited
AZRE
| $309K | ﹤0.01% |
+71,644
| New | +$374K |
|
2529
State Street SPDR S&P Software & Services ETF
XSW
$442M
| $309K | ﹤0.01% |
+2,840
| New | +$311K |
|
2530
Keros Therapeutics
KROS
$197M
| $307K | ﹤0.01% |
+6,400
| New | +$299K |
|
|
ATYR
2531
aTyr Pharma
ATYR
$47.4M
| $307K | ﹤0.01% |
140,296
-35,614
| -20% | -$84K |
|
|
TGH
2532
DELISTED
Textainer Group Holdings limited
TGH
| $304K | ﹤0.01% |
+9,795
| New | +$291K |
|
2533
LGI Homes
LGIH
$1.35B
| $303K | ﹤0.01% |
3,272
-10,637
| -76% | -$972K |
|
2534
iShares S&P Small-Cap 600 Growth ETF
IJT
$8.13B
| $303K | ﹤0.01% |
+2,800
| New | +$308K |
|
2535
AerSale
ASLE
$291M
| $302K | ﹤0.01% |
18,608
-27,080
| -59% | -$471K |
|
2536
Farmers & Merchants Bancorp
FMAO
$483M
| $302K | ﹤0.01% |
11,098
-4,135
| -27% | -$116K |
|
2537
ImmunityBio
IBRX
$7.15B
| $301K | ﹤0.01% |
59,308
+7,718
| +15% | +$42.4K |
|
2538
Century Casinos
CNTY
$32.9M
| $300K | ﹤0.01% |
42,629
-46,152
| -52% | -$338K |
|
2539
Zevia
ZVIA
$118M
| $300K | ﹤0.01% |
+73,266
| New | +$302K |
|
2540
Banner Corp
BANR
$2.38B
| $300K | ﹤0.01% |
+4,740
| New | +$318K |
|
2541
AeroVironment
AVAV
$7.19B
| $298K | ﹤0.01% |
3,482
-10,708
| -75% | -$916K |
|
2542
Compass Diversified
CODI
$752M
| $298K | ﹤0.01% |
+16,361
| New | +$307K |
|
2543
Nu Holdings
NU
$67.8B
| $298K | ﹤0.01% |
73,200
-1,935,131
| -96% | -$8.41M |
|
2544
Purple Innovation
PRPL
$34.5M
| $296K | ﹤0.01% |
+2,468
| New | +$270K |
|
2545
Century Therapeutics
IPSC
$364M
| $295K | ﹤0.01% |
57,498
-643,840
| -92% | -$6.08M |
|
2546
Alaunos Therapeutics
TCRT
$4.64M
| $294K | ﹤0.01% |
3,011
-10,063
| -77% | -$1.46M |
|
|
RAIN
2547
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $293K | ﹤0.01% |
+36,679
| New | +$230K |
|
|
IRS
2548
IRSA Inversiones y Representaciones
IRS
$1.31B
| $291K | ﹤0.01% |
+58,327
| New | +$263K |
|
|
EMKR
2549
DELISTED
Emcore Corp
EMKR
| $290K | ﹤0.01% |
30,173
+1,865
| +7% | +$26.6K |
|
|
GAMB
2550
DELISTED
Gambling.com
GAMB
| $289K | ﹤0.01% |
+31,600
| New | +$273K |
|
Similar funds
Marshall Wace's Q4 2022 Portfolio in Review
As of Q4 2022, Marshall Wace held 3,927 positions worth $44.5B, down 2.6% from $45.6B the previous quarter. Its ten largest holdings account for 9.8% of the portfolio.
Marshall Wace withdrew a net $4.15B in Q4 2022, closing 1,056 positions and reducing 847 holdings. Its most notable exit was Humana, an estimated $383M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Financials and Technology.
Against the trend, Marshall Wace opened a new position in Elevance Health worth $188M.
- Marshall Wace's largest Q4 2022 buy was Elevance Health: 366,649 shares worth $188M.
- Marshall Wace added most to Biogen in Q4 2022, an estimated $309M increase.
- Marshall Wace's biggest Q4 2022 reduction was Johnson & Johnson, cutting an estimated $312M.
- Marshall Wace fully exited Humana in Q4 2022, selling an estimated $383M.
- Marshall Wace's ten largest holdings make up 9.8% of its $44.5B portfolio in Q4 2022.
- Marshall Wace opened 652 new positions and closed 1,056 in Q4 2022.
- Marshall Wace's portfolio value fell 2.6% quarter-over-quarter to $44.5B.
Based on Marshall Wace's 13F filing for Q4 2022, filed 14 Feb 2023.